Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

  • STATUS
    Not Recruiting
  • End date
    Mar 17, 2025
  • participants needed
    164
  • sponsor
    Bayer
Updated on 11 April 2021
systemic therapy
measurable disease
growth factor
BRAF
metastasis
pembrolizumab
epidermal growth factor receptor
ROS1
EGFR
cancer chemotherapy
bisphosphonate
epidermal growth factor
platinum-based chemotherapy
stage iv non-small cell lung cancer
lung carcinoma
proto-oncogene tyrosine-protein kinase ros

Summary

The purpose of the study is to determine the safety and test the efficacy of the combination of radium-223 dichloride and pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC) with bone metastases who either have not received any systemic therapy for their advanced disease or have progressed on prior immunologic checkpoint blockade with antibodies against the programmed cell death protein-(ligand) 1 (PD-1/PD-L1). In this study researchers want to measure tumor shrinkage in response to treatment and how long that shrinkage lasts and gather information on safety. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor. Radium-223 dichloride is an alpha particle-emitting radioactive agent which kills cancer cells.

Details
Condition Non-Small Cell Lung Cancer
Treatment Pembrolizumab, Radium-223 dichloride (Xofigo, BAY 88-8223)
Clinical Study IdentifierNCT03996473
SponsorBayer
Last Modified on11 April 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note